Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.
Pancreatic ductal adenocarcinoma
Proven by pathology
Patients who have not received anti-cancer therapies
Less than 20 years old
Unable to provide inform and consent
Patients who have active malignancy other than pancreatic adenocarcinoma
Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing
Patients with pancreatic ductal adenocarcinoma which are proven by pathology.
Case-control
Prospective
MicroRNA (mir-642b-3p)
GeneticA circulating microRNA in the blood of pancreatic cancer patients.
Ratio of the target microRNA in patients with and without pancreatic adenocarcinoma.
Click on the lead sponsor to view all of their trials.
